26 results
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
petechiae) • Frequent infections ... • Parvovirus infection ... factor (GCSF) treatments ... abnormal under a microscope ... marrow studies Treatment
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... = funny-shaped cells ... risk-stratification • Risks: infection ... only curative treatment ... #treatment #hematology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Treating Isospora belli ... Treating Isospora belli ... CD4 count >200 cells ... evidence of active I. belli ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
CD4 count <100 cells ... CD4 count >100 cells ... decreases to <100 cells ... IDSA #Prevention #Treatment ... #pharmacology
IDSA Algorithm for the Management of Purulent skin and soft tissue infections (SSTIs). 
Mild infection: for
IDSA Algorithm for ... the Management ... 12 000 or <400 cells ... oral antibiotic treatment ... #SSTIs #Algorithm
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
hematopoietic stem cells ... number of CD34+ cells ... number of CD34+ cells ... Number of CD34+ cells ... aplastic anemia Treatment
Rhabdomyolysis - Differential Diagnosis Framework and Management Summary

Causes of Rhabdomyolysis:
 • Trauma:
	- Immobilization
	- Crush injury
	- Compartment
Framework and Management ... Statins - ETOH - Infection ... kidney tubular cells ... Differential #Diagnosis #Management ... #nephrology
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
-6 activates T cells ... Cytokine Activation Syndrome ... respiratory tract infection ... Siltuximab #COVID19 #Pharmacology ... #Management #Medications
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... Release from blast cells ... Differential Diagnosis: Infection ... APML #diagnosis #management
HIV-Associated Neurocognitive Disorder (HAND)

Definition:
HIV-Associated Neurocognitive disorders categories:
• Asymptomatic neurocognitive impairment
• Mild neurocognitive impairment
• HIV dementia

Pathophysiology:
HIV frequently
early stages of infection ... invades mononuclear cells ... CNS ○ Infected cells ... The clinical syndrome ... Treatment: • HAART